Oncology

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.

Manish Agrawal, MD, discusses emerging research on psychedelic-assisted therapy for patients with cancer, including innovative dyadic treatment models, challenges in capturing meaningful outcomes, and growing interest in integrating psychedelics into oncology and palliative care.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

Vitamin D could offer an alternative option over hard-to-access and burdensome cancer drugs to heighten the response of chemotherapy.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

The investigational blood test achieved 99% sensitivity and specificity.

Pharmacists are redefining health care by bridging clinical and economic evidence, making a real difference in patient outcomes through health economics and outcomes research (HEOR).

Pembrolizumab gains FDA approval as a groundbreaking neoadjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Significant challenges persist, particularly in low- and middle-income countries.

The approval of the tablet formulation of zanubrutinib covers all 5 approved indications of the Bruton tyrosine kinase inhibitor.

Taletrectinib demonstrated high response rates and was well tolerated among patients with ROS1+ non-small cell lung cancer (NSCLC).

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).

Asciminib shows superior tolerability over nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, enhancing treatment options and patient outcomes.

Nivolumab plus relatlimab does not significantly improve recurrence-free survival in patients with stage 3, 4 melanoma.

Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option.

A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for patients with relapsed/refractory multiple myeloma without maintenance treatment.

Pharmacists lead the charge in implementing advanced therapeutics, navigating complex challenges and shaping the future of health care innovation.

About 64.1% of patients receiving taxane, trastuzumab, and pertuzumab (THP) without carboplatin had pathological complete response rates (pCRs).

Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.

The investigators suggested that blocking VPS72’s interactions can be a foundation for future therapeutic interventions.

Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.

Compared with standard of care, camizestrant in combination with a CDK4/6 inhibitor shows promise in enhancing progression-free survival (PFS) for patients with advanced breast cancer.